SUPN.1SUPN.1Healthcare · Drug Manufacturers - Specialty & Generic

SUPN.1 Stock Forecast: Supernus, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$29
−0.22% on the day

The 7 Wall Street analysts covering Supernus, Inc. hold a median 12-month price target of $48 — +65.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 17 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
89/ 100
Median analyst target
$48
Analysts covering
7
Revenue$343.0M+13.6% y/y
Operating income$159.0M
Net income$122.0M
Free cash flow$222.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
−6.4%
YTD
−28.6%
1Y
−21.0%
From 52W high
−37.0%
From 52W low
+10.8%
$26
$46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SUPN.1 stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Supernus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
89/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
94
Volatility
94
Growth
94
Momentum
91
Revisions
56
Issuance
55
Accruals
24
Size
20

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (24): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SUPN.1 stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SUPN.1, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26SUPN.1High $87Median $48Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $45Median $48High $87

The green dot is the last close — the median target sits +65.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
9 Nov 2026B of A SecuritiesInitiatesBuy$47
4 Nov 2026Cantor FitzgeraldMaintainsOverweight$67 → $87
4 Nov 2026Piper SandlerReinstatesOverweight$47
28 Oct 2026BarclaysMaintainsOverweight$43 → $45
28 Oct 2026BarclaysMaintainsOverweight—
5 Aug 2026BarclaysMaintainsOverweight—
5 Aug 2026BarclaysMaintainsOverweight$46 → $43
9 July 2026Cantor FitzgeraldMaintainsOverweight—
18 June 2026BarclaysInitiatesOverweight$46
18 June 2026BarclaysInitiatesOverweight—
12 Jan 2026HC Wainwright & Co.MaintainsBuy—
19 Dec 2025StifelMaintainsHold—
31 Oct 2025Piper SandlerReiteratesOverweight—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
29 Oct 2025B of A SecuritiesInitiatesBuy—
23 Oct 2025TD CowenMaintainsBuy—
9 Oct 2025Piper SandlerUpgradeOverweight—
30 Sept 2025Cantor FitzgeraldMaintainsOverweight—
29 Aug 2025Piper SandlerMaintainsNeutral—
27 Aug 2025Craig-HallumMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SUPN.1 appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SUPN.1 vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Supernus, Inc. returned −21.0% against +12.2% for the S&P 500, dividends included.

SUPN.1 vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26SUPN.1S&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SUPN.1 analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−16.8%
Analysts raising
0
Analysts cutting
0
Fundamentals

Supernus, Inc. (SUPN.1) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
40.7×

Cheaper than 18% of US stocks

Price / sales
1.2×

Cheaper than 62% of US stocks

Price / book
1.6×

Cheaper than 48% of US stocks

EV / EBITDA
5.5×

Cheaper than 52% of US stocks

Growth & margins
Revenue growth (YoY)
13.4%

Higher than 61% of US stocks

Earnings growth (YoY)
226.2%

Higher than 91% of US stocks

Gross margin
84.6%

Higher than 94% of US stocks

Operating margin
46.9%

Higher than 96% of US stocks

Net margin
32.8%

Higher than 91% of US stocks

Returns & dividend
Return on equity
−3.6%

Higher than 40% of US stocks

Return on assets
29.3%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Supernus, Inc. (SUPN.1) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Supernus, Inc. has a market value of $1.7B and an enterprise value of $3.6B.

  • Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 13.4% year on year.

  • Net income over the same four quarters: $355.0M, a 26.7% net margin.

  • Diluted earnings per share, trailing twelve months: $2.79.

  • Free cash flow in the twelve months to 30 June 2026: −$111.0M.

  • Supernus, Inc. spent $302.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 58.2M.

  • Trailing P/E: 40.7×; forward P/E: 7.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Supernus, Inc. employs 827 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

SUPN.1 vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SUPN.1Supernus, Inc.$1.7B89
LNTHLantheus Holdings, Inc.$6.6B98
LQDALiquidia Corp.$5.1B97
KNSAKiniksa Pharmaceuticals International Plc$7.3B98
AMRXAmneal Pharmaceuticals, Inc.$7.4B83
ALKSAlkermes Plc$7.5B70
HIMSHims & Hers Health, Inc.$4.1B12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Supernus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SUPN.1 news & analysis

Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

GlobeNewsWire · 10 Nov 2026neutral

Supernus announced that it will participate in the 2026 Jefferies Global Healthcare Conference in London. The excerpt identifies the company as a biopharmaceutical business focused on developing and commercializing products for CNS diseases.

Why it matters — The conference participation is an update on Supernus’s investor and industry engagement.

Why Indivior Pharmaceuticals Stock Topped the Market Today

The Motley Fool · 2 Nov 2026neutral

Indivior Pharmaceuticals stock topped the market today. The excerpt notes that Supernus Pharmaceuticals is the peer and that the combined business will use the Supernus name and stock ticker under an August-announced deal.

Why it matters — INDV watchers may note the deal’s stated company name and ticker for the combined business, as well as its relationship to Supernus.

Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue Estimates

Zacks Investment Research · 29 Oct 2026positive

Indivior Pharmaceuticals reported quarterly earnings of $1.32 per share, above the Zacks Consensus Estimate of $0.93. Earnings were $0.72 per share in the same period a year earlier.

Why it matters — The earnings beat and year-over-year increase are relevant to investors tracking Indivior’s quarterly results.

Indivior Reports Third Quarter 2026 Financial Results

GlobeNewsWire · 29 Oct 2026positive

Indivior reported Q3 2026 total net revenue of $356 million, up 13% year over year, and record quarterly net income of $137 million. SUBLOCADE revenue reached a quarterly record of $267 million, up 22%, and the company said it remains on track to close its merger with Supernus on November 2.

Why it matters — The results highlight year-over-year growth and record quarterly earnings and SUBLOCADE revenue, alongside a stated merger-closing timeline.

FAQ

Frequently asked questions about SUPN.1 stock

What is the SUPN.1 stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Supernus, Inc. have a median 12-month price target of $48, with estimates ranging from $45 to $87. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SUPN.1 stock a buy right now?

Of the 7 analysts covering Supernus, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Supernus, Inc. 89 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SUPN.1?

As at 17 Nov 2026, Supernus, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will SUPN.1 stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +65.7% from the last close, and Ticker Nerd's factor model ranks Supernus, Inc. 89 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SUPN.1 stock forecast for 2030?

No analyst covering Supernus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SUPN.1 are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $87 over the next 12 months.

How has SUPN.1 stock performed over the past year?

Supernus, Inc. returned -21.0% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Supernus, Inc. do?

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases.

What is the latest news on SUPN.1?

The most recent item we track (GlobeNewsWire, 10 Nov 2026): "Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London". Supernus announced that it will participate in the 2026 Jefferies Global Healthcare Conference in London. The excerpt identifies the company as a biopharmaceutical business focused on developing and commercializing products for CNS diseases.

Company

About Supernus, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Supernus Pharmaceuticals, Inc. markets therapies for neurological and psychiatric conditions such as attention-deficit hyperactivity disorder, epilepsy, migraine, Parkinson’s disease-related symptoms, cervical dystonia, chronic sialorrhea, and postpartum depression. Its current portfolio includes branded medicines used in neurology and psychiatry, with products sold primarily in the United States through specialty commercial channels. The company also maintains research and development programs aimed at advancing new CNS treatments and strengthening its neuroscience portfolio. Headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. plays a notable role in the specialty pharmaceutical market by addressing a broad range of chronic and complex disorders affecting the central nervous system.

CEO Mr. Jack A. Khattar M.B.A. · 827 employees · United States · https://www.supernus.com